Recent Finacing
Recent Raise
Oxyrane develops enzyme replacement therapies for lysosomal storage diseases using a proprietary Yarrowia lipolytica yeast platform to produce human‑glycosylated enzymes with increased mannose‑6‑phosphate and cellular uptake.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors